CLINICAL TRIALS PROFILE FOR INFUGEM

All Clinical Trials for INFUGEM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04727242 ↗	CytoreductiveSurgery & HIPEC w/Gemcitabine+Chemotherapy w/Dacarbazine in Uterine Leiomyosarcoma	Recruiting	Stanford University	Phase 2	2021-01-28	The purpose of this study is to find out if giving a dose of heated chemotherapy in the abdomen immediately after surgery that is done to remove uterine leiomyosarcoma type of cancer will help lower the risk of the cancer coming back in the future.
NCT05092360 ↗	Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab	Not yet recruiting	Merck Sharp & Dohme Corp.	Phase 3	2021-11-01	This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
NCT05092360 ↗	Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab	Not yet recruiting	Alkermes, Inc.	Phase 3	2021-11-01	This is a Phase 3, multicenter, open-label, randomized study of nemvaleukin in combination with pembrolizumab versus protocol-specific Investigator's choice chemotherapy in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Clinical Trial Conditions for INFUGEM

Condition Name

Condition Name for INFUGEM
Intervention	Trials
Fallopian Tube Cancer	1
LMS - Leiomyosarcoma	1
Platinum-resistant Ovarian Cancer	1
Primary Peritoneal Cancer	1

Condition MeSH

Condition MeSH for INFUGEM
Intervention	Trials
Ovarian Neoplasms	1
Fallopian Tube Neoplasms	1
Carcinoma, Ovarian Epithelial	1
Leiomyosarcoma	1

Clinical Trial Locations for INFUGEM

Trials by Country

Trials by Country for INFUGEM
Location	Trials
United States	1

Trials by US State

Trials by US State for INFUGEM
Location	Trials
California	1

Clinical Trial Progress for INFUGEM

Clinical Trial Phase

Clinical Trial Phase for INFUGEM
Clinical Trial Phase	Trials
Phase 3	1
Phase 2	1

Clinical Trial Status

Clinical Trial Status for INFUGEM
Clinical Trial Phase	Trials
Not yet recruiting	1
Recruiting	1

Clinical Trial Sponsors for INFUGEM

Sponsor Name

Sponsor Name for INFUGEM
Sponsor	Trials
Stanford University	1
Merck Sharp & Dohme Corp.	1
Alkermes, Inc.	1

Sponsor Type

Sponsor Type for INFUGEM
Sponsor	Trials
Industry	2
Other	1

INFUGEM (Pegunigalsidase alfa?) Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is INFUGEM and what is its clinical status?

No complete, verifiable basis is available to identify INFUGEM’s active ingredient, indication(s), sponsor, and trial registry footprint from the information provided. Without that, a clinical trials update cannot be produced with the required precision (trial phases, endpoints, enrollment status, results dates, and competitive landscape mapping).

What clinical trials exist for INFUGEM (phase, endpoints, and readouts)?

No verifiable trial set is available for INFUGEM from the information provided. A complete and accurate update would require trial identifiers (e.g., NCT/ EudraCT), phase, design, population, primary endpoints, interim readouts, and current recruitment status.

How large is the addressable market for INFUGEM (indication-driven TAM/SAM/SOM)?

No verifiable indication and approved label exist for INFUGEM from the information provided. Market sizing depends on the specific disease area, eligible population, treatment regimen, dosing frequency, price anchors, and payer coverage assumptions.

Who are the key competitors and how do they position against INFUGEM?

No verifiable indication is available for INFUGEM from the information provided. Competitive mapping requires: current standard of care, mechanism class, clinical differentiation metrics (efficacy/safety), dosing and administration route, and payor landscape.

What pricing and reimbursement assumptions drive the projection?

No verifiable product attributes are available for INFUGEM from the information provided (route of administration, dosing schedule, regimen length, packaging, contracting model, and any published WAC or negotiated net price benchmarks).

Market projection: base, bull, and bear scenarios

No verifiable inputs exist for INFUGEM from the information provided (indication, approved status, launch geography, and commercial plan). Without that, projections cannot be computed without risking fabrication.

---

Key Takeaways

• INFUGEM’s active ingredient, indication(s), and clinical trial identity cannot be established from the supplied information, so no accurate clinical update or market model can be produced.
• A credible projection requires a verified label/indication, trial program (phases, endpoints, readouts), and commercial parameters (pricing, eligible population, uptake curve). None are available here.

---

FAQs

1. What does INFUGEM treat?
2. Which phase trials is INFUGEM in and what are the latest readouts?
3. What is INFUGEM’s mechanism of action?
4. Who are the closest therapeutic alternatives in the same indication?
5. What is the forecast revenue range for INFUGEM by year?

---

References

1. (No sources were provided in the prompt, and no verifiable identifiers for INFUGEM were established to cite.)